Abstract
The efficacy of the intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents bevacizumab and ranibizumab has revolutionized the treatment of neovascular age-related macular degeneration. Results from the Comparison of AMD Treatments Trials (CATT), the Alternative Treatments to Inhibit VEGF in Patients with Age-Related Choroidal Neovascularisation (IVAN) trial, and other multicenter randomized clinical trials that compared bevacizumab and ranibizumab indicate that both drugs provide dramatic and lasting visual improvements for patients. However, results from these trials also make clear that there is individual variation in the initial response to therapy and in the durability of the clinical effect. Genetic assessment of participants in these trials provides an ideal opportunity to investigate pharmacogenetic associations using rigorously defined phenotypic data.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
